Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Position Trading in Canada -- Ignore unavailable to you. Want to Upgrade?

To: keith massey who wrote (173)	12/16/1998 1:03:00 AM
From: Essam Hamza	Read Replies (1) \| Respond to of 2259

Thanks Keith. Well I just came back from a talk and the speaker and the drug rep from pfizer were all gungho about celebrex. I do know that for myself I plan on using it for most of my patients with arthritis at the very least. Once it's effectiveness and safety is fully established I wouldn't hesitate to use it for other pain conditions and syndromes. I disagree that doctors will stick with the general nsaids. In the US the cost may be a deterent you would think but then look at Viagra. It cost what $10CDN a pill and I have patients crossing the border snapping them up. Believe me Keith, the medical community is very excited about COX-2. My only concern was the competion from Merk. They have two other similar drugs coming out but are at least 6mths behind in their application process. Oh yea, it looks like MTC actually has the COX-2 drug that PFE will be marketing. Anyways thanks for the comments. I will watch for a pullback and bottom before accumulating. Essam.